[18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT
European Journal of Nuclear Medicine and Molecular Imaging · 2023-03 · 50 (4) · 1205-1215
DOI: 10.1007/s00259-022-06067-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.12.2022. Verfasst von Xingyu Mu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital, Guilin Medical University, Guilin, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to assess the diagnostic performance of [ 18 F]FAPI-42 PET/CT and compare it with that of 2-[ 18 F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies.
Methods
A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [ 18 F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[ 18 F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [ 18 F]FAPI-42 PET/CT and biomarkers affecting the uptake of [ 18 F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [ 18 F]FAPI-42 and 2-[ 18 F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated.
Results
A total of 161 lesions were detected in 27 (64%) patients on [ 18 F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV max , 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV max : 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[ 18 F]FDG than that of [ 18 F]FAPI-42 (SUV max , 2.6 versus 2.1; P = 0.026). However, the SUV max of [ 18 F]FAPI-42 was higher than that of 2-[ 18 F]FDG in local recurrences and lymphatic lesions (SUV max , 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05). Conclusion [ 18 F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [ 18 F]FAPI-42 PET/CT is comparable with that of 2-[ 18 F]FDG PET/CT in such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Affiliated Hospital, Guilin Medical University, Guilin, China.
- Department of Vascular Intervention, Affiliated Hospital, Guilin Medical University, Guilin, China.
- Department of Nuclear Medicine, Affiliated Hospital, Guilin Medical University, Guilin, China. fuwei19700513@163.com.
- Department of Vascular Intervention, Affiliated Hospital, Guilin Medical University, Guilin, China. maojingsong163@163.com.
- Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, Xiamen, 361101, China. maojingsong163@163.com.
Zitieren
APA
Mu, X., Huang, X., Jiang, Z., Li, M., Jia, L., Lv, Z., Fu, W., & Mao, J. (2023). [18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 50(4), 1205-1215. https://doi.org/10.1007/s00259-022-06067-2
Vancouver
Mu X, Huang X, Jiang Z, Li M, Jia L, Lv Z, et al. [18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(4):1205-1215. doi:10.1007/s00259-022-06067-2
BibTeX
@article{Mu2023,
author = {Mu, Xingyu and Huang, Xiaoxue and Jiang, Zewen and Li, Meng and Jia, Lulu and Lv, Zhongyuan and Fu, Wei and Mao, Jingsong},
title = {[18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {50},
number = {4},
pages = {1205--1215},
doi = {10.1007/s00259-022-06067-2}
}
EUVIMED